The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Phase 1 dosing is expected to finish by the end of 2025
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Subscribe To Our Newsletter & Stay Updated
